Danish biotechnology company specializing in monoclonal and bispecific antibodies for cancer and autoimmune diseases; developed the proprietary HuMab-Mouse and UniBody platforms.
相关临床试验
276
172 进行中
药物批准
3
批准总数
监管机构
3
监管机构数
成立时间
1999
进行中（未招募）
168
60.9%
Approved For Marketing
1
0.4%
已完成
18
6.5%
尚未招募
4
1.4%
招募中
59
21.4%
暂停
1
0.4%
终止
22
8.0%
撤回
3
1.1%
- The advanced endometrial cancer pipeline is expanding rapidly, with immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) driving a more competitive and biomarker-driven market. - Merck's Phase III TroFuse-005 trial met its primary endpoints of overall survival and progression-free survival for the investigational TROP2-directed ADC sacituzumab tirumotecan in advanced or recurrent endometrial cancer. - Genmab's rinatabart sesutecan (Rina-S) achieved a 50.0% confirmed objective response rate, including two complete responses, in heavily pretreated advanced endometrial cancer patients. - The global endometrial cancer market is forecast to grow from USD 30.60 billion in 2025 to USD 40.66 billion by 2031, at a CAGR of 4.86%.
- China's NMPA has approved TIVDAK (tisotumab vedotin) as the first antibody-drug conjugate for previously treated recurrent or metastatic cervical cancer in China. - The approval is supported by the global Phase 3 innovaTV 301 trial, which showed a statistically significant overall survival benefit (HR=0.70, p=0.0038) versus chemotherapy. - The China subpopulation demonstrated a 45% reduction in the risk of death (HR: 0.55), with consistent benefit regardless of prior anti-PD(L)1 therapy exposure. - Approximately 150,000 new cervical cancer cases are diagnosed annually in China, where treatment options remain limited after chemotherapy failure.
- The global AI in antibody discovery market was valued at USD 546.17 million in 2025 and is projected to reach USD 3,162.19 million by 2034, expanding at a CAGR of 21.57%. - North America dominated the market with a 43.72% share in 2025, while the Asia Pacific region is expected to grow at the fastest rate with a CAGR of 23.26%. - Monoclonal antibodies accounted for the largest antibody modality share at 54.41%, driven by established clinical pathways and abundant training datasets for AI model development. - Structure prediction technology led the market with a 32.12% share in 2025, while generative AI and protein language models are forecast to grow at a CAGR of 22.33%.
- The frontMIND phase 3 trial demonstrated that adding tafasitamab and lenalidomide to standard R-CHOP therapy reduced progression or death risk by 25% in patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell lymphoma. - This represents only the second randomized phase 3 trial in 25 years to show improved primary efficacy outcomes compared to R-CHOP alone for newly diagnosed DLBCL patients. - The combination achieved 67.3% three-year progression-free survival versus 60.7% with R-CHOP alone, with benefits observed across all patient subgroups including molecular subtypes. - The regimen showed manageable toxicity profiles and maintained high R-CHOP dose delivery, positioning it as a potential new standard of care for high-risk aggressive B-cell lymphomas.
- LTZ Therapeutics completed an oversubscribed $38 million financing round led by GL Ventures to accelerate development of its Universal Myeloid Cell Engager immunotherapy platform. - The funding brings total capital raised since the company's 2022 founding to approximately $130 million and will support ongoing Phase 1 trials of lead asset LTZ-301. - LTZ-301 is a bispecific antibody targeting CD79b-positive B-cells in relapsed or refractory Non-Hodgkin Lymphoma by redirecting myeloid cells to enhance cancer cell destruction. - The company appointed Erin Lavelle, former COO and CFO of ProfoundBio, as an independent board director to guide strategic operations during this growth phase.
- Hemab Therapeutics, a clinical-stage biotech developing subcutaneous prophylactic therapies for serious bleeding disorders, filed for an initial public offering on NASDAQ under ticker "COAG." - The company's lead asset sutacimig (HMB-001) is a bispecific antibody in Phase 1/2 development for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, with Phase 3 planned. - IPO proceeds will fund late-stage development of sutacimig and HMB-002 for Von Willebrand Disease, targeting approximately 130,000 patients across key global markets. - The company has raised approximately $346 million since inception and holds multiple regulatory designations including FDA Fast Track and Breakthrough Therapy status for sutacimig.
- Anthropic has acquired New York-based biotech AI startup Coefficient Bio in a stock deal valued at over $400 million, marking a significant expansion into life sciences and drug discovery. - The acquisition brings a specialized team of fewer than 10 researchers with computational biology backgrounds from Genentech into Anthropic's healthcare division. - Coefficient Bio had developed a platform capable of automating biotech workflows including research planning, clinical regulatory strategies, and drug candidate identification. - The deal represents a strategic shift from Anthropic's previous approach of adapting general-purpose Claude models to building biology-specific AI systems from the ground up.
- Lundbeck's Phase 1b trial of Lu AF28996, a novel dopamine D1/D2 receptor agonist, demonstrated good tolerability and early signals consistent with its mechanism of action in advanced Parkinson's disease patients. - The oral investigational therapy aims to address motor fluctuations and "OFF" time periods that persist despite current treatments in advanced Parkinson's disease. - Based on positive Phase 1 results, Lundbeck is initiating a Phase 2 study in 2026 to further evaluate Lu AF28996's potential in advanced Parkinson's disease patients. - The company also presented advances in multiple system atrophy research, including progress on its amlenetug pivotal program for this fatal neurodegenerative disease with no approved treatments.
- NICE has reversed its initial rejection and now recommends Genmab's Tivdak (tisotumab vedotin) for NHS use in recurrent or metastatic cervical cancer patients. - The approval follows improvements to Genmab's economic model incorporating real-world evidence from five-year patient follow-up data and updated cost comparisons. - Tivdak demonstrated a 30% reduction in death risk with median overall survival of 11.5 months versus 9.5 months for chemotherapy in the innovaTV 301 trial. - The Cancer Drugs Fund will provide initial coverage for approximately 117 eligible patients in England before routine NHS commissioning begins.
- A comprehensive research report reveals 90 CD137-targeted therapies currently in clinical trials, representing a significant expansion in cancer immunotherapy development. - Major pharmaceutical companies including Roche, Genmab, and Sichuan Baili Pharmaceutical are actively advancing CD137-targeting therapies across multiple cancer indications. - Innovative technology platforms like AP Biosciences' T-cube enable creation of bispecific antibodies that selectively activate T-cells through CD137, potentially minimizing cytokine storm toxicities. - Combination therapy approaches combining CD137 agonists with checkpoint inhibitors and other targeted treatments show promise for overcoming monotherapy limitations.
